-
1
-
-
27144550160
-
Arming antibodies: Prospects and changes for immunoconjugates
-
Wu AM, Senter PD. Arming antibodies: prospects and changes for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
-
(2005)
Nat Biotechnol
, vol.23
, pp. 1137-1146
-
-
Wu, A.M.1
Senter, P.D.2
-
3
-
-
80054037204
-
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates
-
FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9.
-
(2011)
Cancer Res
, vol.71
, pp. 6300-6309
-
-
Fitzgerald, D.J.1
Wayne, A.S.2
Kreitman, R.J.3
Pastan, I.4
-
4
-
-
84861542159
-
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
-
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-8.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1822-1828
-
-
Kreitman, R.J.1
Tallman, M.S.2
Robak, T.3
Coutre, S.4
Wilson, W.H.5
Stetler-Stevenson, M.6
-
5
-
-
84859156821
-
A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia
-
Wayne AS, Bhojwani D, Silverman LB, Richards K, Stetler-Stevenson M, Shah N, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia. Blood 2011;118:1317a.
-
(2011)
Blood
, vol.118
-
-
Wayne, A.S.1
Bhojwani, D.2
Silverman, L.B.3
Richards, K.4
Stetler-Stevenson, M.5
Shah, N.6
-
6
-
-
3042621639
-
Mesothelin: A new target for immunotherapy
-
Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 3937-3942
-
-
Hassan, R.1
Bera, T.2
Pastan, I.3
-
7
-
-
34548858453
-
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. Infusion to patientswith mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
-
Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kinderler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patientswith mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5144-5149
-
-
Hassan, R.1
Bullock, S.2
Premkumar, A.3
Kreitman, R.J.4
Kinderler, H.5
Willingham, M.C.6
-
8
-
-
84855845644
-
Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response
-
(abstr 7026)
-
Hassan R, Sharon E, Schuler B, Mallory Y, Zhang J, Ling A, et al. Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. J Clin Oncol 29:2011 (suppl; abstr 7026).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Hassan, R.1
Sharon, E.2
Schuler, B.3
Mallory, Y.4
Zhang, J.5
Ling, A.6
-
9
-
-
36749029362
-
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors
-
Zhang Y, Xiang X, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007;104:17099-104.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 17099-17104
-
-
Zhang, Y.1
Xiang, X.2
Hassan, R.3
Pastan, I.4
-
10
-
-
77954566627
-
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of Pseudomonas exotoxin-based proteins to the cell cytosol
-
Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of Pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther 2010;9:2007-15.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2007-2015
-
-
Traini, R.1
Ben-Josef, G.2
Pastrana, D.V.3
Moskatel, E.4
Sharma, A.K.5
Antignani, A.6
-
11
-
-
77954361875
-
Pseudomonas exotoxin Amediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1
-
Du X, Youle RJ, Fitzgerald DJ, Pastan I. Pseudomonas exotoxin Amediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol 2010;30:3444-52.
-
(2010)
Mol Cell Biol
, vol.30
, pp. 3444-3452
-
-
Du, X.1
Youle, R.J.2
Fitzgerald, D.J.3
Pastan, I.4
-
12
-
-
0031438704
-
Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins
-
Chiron MF, Fryling CM, Fitzgerald DJ. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem 1997;272:3107-11.
-
(1997)
J Biol Chem
, vol.272
, pp. 3107-3111
-
-
Chiron, M.F.1
Fryling, C.M.2
Fitzgerald, D.J.3
-
13
-
-
73849122818
-
Drug targeting: Learning from toxin entry and trafficking in mammalian cells
-
Spooner RA, Watson P. Drug targeting: learning from toxin entry and trafficking in mammalian cells. Curr Opin Drug Discov Dev 2010;13: 86-95.
-
(2010)
Curr Opin Drug Discov Dev
, vol.13
, pp. 86-95
-
-
Spooner, R.A.1
Watson, P.2
-
14
-
-
81555214408
-
Guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
-
Weldon JE, Pastan I. Guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011;278:4683-700.
-
(2011)
FEBS J
, vol.278
, pp. 4683-4700
-
-
Weldon, J.E.1
Pastan, I.2
-
15
-
-
84875971904
-
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin
-
Liu XF, FitzGerald DJ, Pastan I. The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin. Cancer Res 2013;73:2281-8.
-
(2013)
Cancer Res
, vol.73
, pp. 2281-2288
-
-
Liu, X.F.1
Fitzgerald, D.J.2
Pastan, I.3
-
16
-
-
0031439247
-
Cellular functions regulated by SRC family kinases
-
Thomas SM, Brugge JS. Cellular functions regulated by SRC family kinases. Annu Rev Cell Dev Biol 1997;13:513-609.
-
(1997)
Annu Rev Cell Dev Biol
, vol.13
, pp. 513-609
-
-
Thomas, S.M.1
Brugge, J.S.2
-
17
-
-
7944236785
-
Src family kinases, key regulators of signal transduction
-
Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004;23:7906-9.
-
(2004)
Oncogene
, vol.23
, pp. 7906-7909
-
-
Parsons, S.J.1
Parsons, J.T.2
-
18
-
-
84855466843
-
Regulation of Src family kinases in human cancers
-
Sen B, Johnson FM. Regulation of Src family kinases in human cancers. J Signal Transduct 2011;2011:865819.
-
(2011)
J Signal Transduct
, vol.2011
, pp. 865819
-
-
Sen, B.1
Johnson, F.M.2
-
19
-
-
1642416839
-
Recombinant immunotoxins in the treatment of cancer
-
Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004;248:503-18.
-
(2004)
Methods Mol Biol
, vol.248
, pp. 503-518
-
-
Pastan, I.1
Beers, R.2
Bera, T.K.3
-
20
-
-
84859434519
-
CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis
-
Liu XF, Xiang L, Zhang Y, Becker KG, Bera TK, Pastan I. CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis. Oncogene 2012;31:1673-82.
-
(2012)
Oncogene
, vol.31
, pp. 1673-1682
-
-
Liu, X.F.1
Xiang, L.2
Zhang, Y.3
Becker, K.G.4
Bera, T.K.5
Pastan, I.6
-
21
-
-
11344295069
-
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments
-
Tan M, Fang HB, Tian GL, Houghton PJ. Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med 2004;24:109-19.
-
(2004)
Stat Med
, vol.24
, pp. 109-119
-
-
Tan, M.1
Fang, H.B.2
Tian, G.L.3
Houghton, P.J.4
-
22
-
-
0034458943
-
SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling
-
Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000;20:9018-27.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 9018-9027
-
-
Blake, R.A.1
Broome, M.A.2
Liu, X.3
Wu, J.4
Gishizky, M.5
Sun, L.6
-
23
-
-
77953440232
-
Bosutinib: A dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia
-
Keller G, Schafhausen P, Brummendorf TH. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Exp Rev Hematol 2009;2:489-97.
-
(2009)
Exp Rev Hematol
, vol.2
, pp. 489-497
-
-
Keller, G.1
Schafhausen, P.2
Brummendorf, T.H.3
-
24
-
-
33750057983
-
Perlecan proteolysis induces an α2β1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation
-
Laplante P, Raymond MA, Labelle A, Abe J, Iozzo RV, Hébert MJ. Perlecan proteolysis induces an α2β1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J Biol Chem 2006;281: 30383-92.
-
(2006)
J Biol Chem
, vol.281
, pp. 30383-30392
-
-
Laplante, P.1
Raymond, M.A.2
Labelle, A.3
Abe, J.4
Iozzo, R.V.5
Hébert, M.J.6
-
25
-
-
84860482801
-
Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells
-
Eguchi R, Kubo S, Takeda H, Ohta T, Tabara C, Ogawa H, et al. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells. Carcinogenesis 2012;33:969-75.
-
(2012)
Carcinogenesis
, vol.33
, pp. 969-975
-
-
Eguchi, R.1
Kubo, S.2
Takeda, H.3
Ohta, T.4
Tabara, C.5
Ogawa, H.6
-
26
-
-
0023352242
-
Identification of a human gene (HCK) that encodes a proteintyrosine kinase and is expressed in hemopoietic cells
-
Quintrell N, Lebo R, Varmus H, Bishop JM, Pettenati MJ, Le Beau MM, et al. Identification of a human gene (HCK) that encodes a proteintyrosine kinase and is expressed in hemopoietic cells. Mol Cell Biol 1987;7:2267-75.
-
(1987)
Mol Cell Biol
, vol.7
, pp. 2267-2275
-
-
Quintrell, N.1
Lebo, R.2
Varmus, H.3
Bishop, J.M.4
Pettenati, M.J.5
Le Beau, M.M.6
-
27
-
-
0030008394
-
Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions
-
Lowell CA, Fumagalli L, Berton G. Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. J Cell Biol 1996;133:895-910.
-
(1996)
J Cell Biol
, vol.133
, pp. 895-910
-
-
Lowell, C.A.1
Fumagalli, L.2
Berton, G.3
-
28
-
-
49049119270
-
Hematopoietic cell kinase (Hck) isoforms and phagocyte duties-from signaling and actin reorganization to migration and phagocytosis
-
Guiet R, Poincloux R, Castandet J, Marois L, Labrousse A, Le Cabec V, et al. Hematopoietic cell kinase (Hck) isoforms and phagocyte duties-from signaling and actin reorganization to migration and phagocytosis. Eur J Cell Biol 2008;87:527-42.
-
(2008)
Eur J Cell Biol
, vol.87
, pp. 527-542
-
-
Guiet, R.1
Poincloux, R.2
Castandet, J.3
Marois, L.4
Labrousse, A.5
Le Cabec, V.6
-
29
-
-
79952269646
-
A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma
-
Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT, Testa JR. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 2010;1:496-505.
-
(2010)
Genes Cancer
, vol.1
, pp. 496-505
-
-
Menges, C.W.1
Chen, Y.2
Mossman, B.T.3
Chernoff, J.4
Yeung, A.T.5
Testa, J.R.6
-
30
-
-
34447316429
-
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
-
Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007;6: 1962-72.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 1962-1972
-
-
Tsao, A.S.1
He, D.2
Saigal, B.3
Liu, S.4
Lee, J.J.5
Bakkannagari, S.6
-
31
-
-
77955713928
-
Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
-
Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ 2010;17:1381-91.
-
(2010)
Cell Death Differ
, vol.17
, pp. 1381-1391
-
-
Harr, M.W.1
Caimi, P.F.2
McColl, K.S.3
Zhong, F.4
Patel, S.N.5
Barr, P.M.6
-
32
-
-
76349089751
-
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth
-
Ke J, Chelvarajan RL, Sindhava V, Robertson DA, Lekakis L, Jennings CD, et al. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol Cancer 2009;8:132.
-
(2009)
Mol Cancer
, vol.8
, pp. 132
-
-
Ke, J.1
Chelvarajan, R.L.2
Sindhava, V.3
Robertson, D.A.4
Lekakis, L.5
Jennings, C.D.6
|